Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

Plain-language summary

This study aims to provide long-term follow-up for participants who received the LX2020 gene therapy for arrhythmogenic cardiomyopathy (a disease of the heart muscle) caused by a disease-causing variant in the PKP2 (plakophilin-2) gene. It can include people who previously received this gene therapy in the LX2020-01 study. This is a non-phase study and is enrolling participants by invitation.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Enrolling by invitation

Sponsor

Lexeo Therapeutics

Start date

8/29/2025

Estimated completion

8/1/2030

Countries

United States

Related genes

Locations

• Ann Arbor, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Participants who received LX2020 in study LX2020-01

Exclusion Criteria:

* Concurrent enrollment in any other clinical investigation involving use of an investigational agent.